Scope and Claims Analysis of US Patent 6,406,715 (Intermediate-Release Nicotinic Acid With Urinary Metabolite Pathway Profile)

US 6,406,715 covers an oral, once-daily intermediate-release nicotinic acid (niacin) product intended to treat hyperlipidemia while avoiding drug-induced discontinuation triggers tied to hepatotoxicity and to elevations in uric acid and/or glucose. The claim scope is anchored on a specific formulation architecture (nicotinic acid plus a swelling agent) and on a defined in vivo/in vitro urinary metabolite signature that reflects controlled absorption and dominance of “Pathway 2” metabolites over unmetabolized nicotinic acid in urine, measured across multiple dose strengths (about 1,000 mg, 1,500 mg, 2,000 mg, and 2,500 mg) with dependent claims locking tablet splits (500 mg, 750 mg, or 1,000 mg per tablet).

What patents protect intermediate-release nicotinic acid once daily for hyperlipidemia without hepatotoxicity?

US 6,406,715 is a formulation-and-performance claims patent: it is not merely about sustained/extended release niacin; it is about a niacin dosage form that uses a swelling agent to create an “intermediate release” profile and is defined by urinary metabolite proportions consistent with controlled release and absorption.

Core claim concept: release control proven by urinary metabolite ratios

Claims 1, 5, and 9 establish three functional/analytical pillars:

Indication and dosing regimen
- Oral administration, once-a-day as a single dose
- For treating hyperlipidemia
Safety/discontinuation target
- Avoid drug-induced hepatotoxicity (claims 1/5/9 explicitly include hepatotoxicity)
- Also avoid elevations in uric acid or glucose or both to levels requiring discontinuation (claims 1/9; claims 5 covers immediate-release; see below)
Formulation + performance signature
- Contains nicotinic acid + swelling agent
- Has a urinary metabolite profile (in vitro urinary metabolite profile referenced as resulting from absorption after oral administration)
- For each tested oral dose, the urine must contain:
  - (a) “nicotinic acid present in urine” as a defined percentage range
  - (b) “Pathway 2 metabolites” present in urine as a complementary percentage range

This means the patent is likely to be interpreted as requiring, in infringement and validity disputes, chemistry plus a biomarker-driven performance envelope.

Intermediate-release vs immediate-release claim language

The independent structure appears twice with different release characterization:

Claim 1: intermediate release formulation, described with urinary metabolite ranges at ~1000 mg dosing.
Claim 5: immediate release formulation, described with urinary metabolite ranges at ~1500 mg dosing.
Claim 9: intermediate release formulation again, with urinary metabolite ranges at ~2000 mg dosing.
Claims 13–16: intermediate release at ~2500 mg dosing.

That mix matters because it broadens what “the estate” of 6,406,715 could cover in practice: the same overall concept (swelling-agent niacin + urinary metabolite proportions) may be framed differently by release class across separate groups of claims.

How claim construction is likely to work

The claim language is unusually specific for a small-molecule oral formulation patent. Three claim-construction hotspots typically dominate litigation:

“Swelling agent” scope
- Likely covers excipients that swell in GI fluids to modulate dissolution/erosion and intermediate-release behavior.
- Competitor designs may attempt to use different release-controlling polymers or matrices to argue non-equivalence and non-infringement.
“Intermediate release” definitional ambiguity
- “Intermediate release” can be argued as a release-rate category requiring consistency with the patent’s own urinary metabolite outcome measurement methods.
- The presence of biomarker ranges reduces purely interpretive fight: accused products can be tested for urinary metabolite ratios.
“Pathway 2 metabolites”
- This is a major interpretive and evidentiary anchor. The term must map to the patent’s specified metabolic pathway labeling.
- If an accused product yields a different metabolic distribution (higher unmetabolized nicotinic acid fraction or different pathway metabolite ratios), infringement becomes testable.

Patent estate breadth inference

With only the single patent number and claim text provided, the only defensible conclusion is the scope inside US 6,406,715. Identifying other patents in the same family or related estates would require record-level data (Orange Book/Nor approvals/patent family). No such data is included in the prompt, so analysis below stays inside the asserted claims.

What are the exact claim ranges and urinary metabolite performance requirements in US 6,406,715?

Claim 1: intermediate release at ~1000 mg

Claim 1 requires, for a dose “about 1000 mg”:

Nicoti nic acid in urine: 4.0% to 26%
Pathway 2 metabolites in urine: 74% to 95%

Also required:

Once daily, single dose
Treat hyperlipidemia
Intermediate-release
Nocotinic acid + swelling agent
Avoid discontinuation due to drug-induced hepatotoxicity and elevations in uric acid or glucose or both

Claim 2: mean profile for claim 1

Dependent claim 2 narrows the performance to means:

Nicotinic acid in urine: about 12%
Pathway 2 metabolites: about 88%

Claim 3–4: tablet splitting at 1000 mg total

Claim 3 and 4 depend on claim 1 and 2 respectively:

Two tablets
Each tablet contains ~500 mg nicotinic acid

Claim 5: immediate release at ~1500 mg

Claim 5 covers an “immediate release nicotinic acid formulation,” once daily, single dose, with safety/dosing and with urinary metabolite ranges at about 1500 mg:

Nicotinic acid in urine: 11.0% to 45%
Pathway 2 metabolites in urine: 55% to 89%

Claim 6: mean profile for claim 5

Nicotinic acid: about 21%
Pathway 2 metabolites: about 79%

Claim 7–8: tablet splitting at 1500 mg total

Two tablets
Each tablet contains ~750 mg nicotinic acid

Claim 9: intermediate release at ~2000 mg

Claim 9 recites intermediate release at about 2000 mg:

Nicotinic acid in urine: 22% to 48%
Pathway 2 metabolites in urine: 52% to 78%

Safety requirements:

Once daily, single dose
Hyperlipidemia
Avoid hepatotoxicity and uric acid or glucose elevations requiring discontinuation
Nicotinic acid + swelling agent
Urinary metabolite profile linked to absorption from the intermediate-release formulation

Claim 10: mean profile for claim 9

Nicotinic acid: about 32%
Pathway 2 metabolites: about 68%

Claim 11–12: tablet splitting at 2000 mg total

Two tablets
Each tablet contains ~1000 mg nicotinic acid

Claim 13: intermediate release at ~2500 mg

Claim 13 sets intermediate-release at about 2500 mg:

Nicotinic acid in urine: 25% to 66%
Pathway 2 metabolites: 34% to 75%

Claim 14: mean profile for claim 13

Nicotinic acid: about 42%
Pathway 2 metabolites: about 58%

Claim 15–16: tablet splitting at 2500 mg total

Three tablets
Each tablet contains ~1000 mg nicotinic acid

How does the urinary metabolite profile define infringement risk for competing niacin formulations?

Quantitative infringement test logic

The presence of bounded urine percentages creates a direct infringement pathway:

An accused product must fit:
- the swelling-agent niacin formulation architecture, and
- produce an in vivo urinary metabolite profile falling within the claimed ranges for the relevant dose group (1000 mg, 1500 mg, 2000 mg, 2500 mg).

If metabolite ratios fall outside ranges, claim elements likely fail.

Key litigation risk points

Analytical method alignment
- Claims say “in vitro urinary metabolite profile resulting from absorption … following oral administration.”
- Accused infringers will target the correspondence between “in vitro profile” and the claimed “resulting from absorption.” If methods differ, equivalence arguments may arise.
Dose-matching
- Ranges are dose-specific: 1000 mg, 1500 mg, 2000 mg, 2500 mg.
- A competitor can shift dosing format or mg strength; if their administered dose does not fall into “about” ranges used in the claims, infringement may be harder.
Release-class framing
- The estate includes both intermediate-release and immediate-release claim sets.
- A product marketed/engineered as immediate-release may still be tested against intermediate-release claims if performance matches, but the release classification could be a factual question.
“Swelling agent” material selection
- If a competitor uses a different release-controlling approach (non-swelling matrix, osmotic pump, lipid matrix, bead technology) it can argue non-inclusion of “swelling agent.”
- Even when swelling agents exist, competitors can argue that the swelling mechanism is not the one used by the patented formulation intended to produce the claimed urinary signature.

When does this patent lose exclusivity? (US 6,406,715 term and expiry timing)

No filing/priority date, patent grant date beyond the number, or maintenance/terminal disclaimer data is provided in the prompt. Without those records, no accurate exclusivity-loss date can be computed from the patent number alone.

What is the Orange Book status of US 6,406,715?

The prompt provides no Orange Book entry data (application numbers, listed patents, expiration dates, or exclusivity codes). No accurate Orange Book status can be stated.

What FDA regulatory pathway issues connect to urinary metabolite performance claims?

No NDA/ANDA/BLA identifiers or FDA approval documentation are provided. Without them, no binding analysis of regulatory pathway timing, patent listing triggers, or regulatory-review linkage can be made.

How strong is the patent estate for intermediate-release niacin: formulation + biomarker claims?

Based only on the claim text, the enforceability profile is shaped by two competing features:

Strength factors
- Claims require specific formulation composition (nicotinic acid + swelling agent).
- Claims require specific performance biomarker ranges tied to urine metabolite distributions.
- The quantitative bounds can be directly tested on accused products.
Vulnerability factors
- The claim uses broad functional descriptors that could be contested:
  - “intermediate release” and “immediate release” without quantitative dissolution-time definitions in the excerpt.
  - “Pathway 2 metabolites” depends on the patent’s definition and the existence of a consistent metabolite mapping across assays.

From a litigation/strategy standpoint, the most consequential strength is that biomarker ratios provide objective gates. The most consequential vulnerability is interpretive: how “Pathway 2 metabolites” are defined and measured, and whether accused products can show different urinary distributions due to formulation differences or study design differences.

What generic entry risks exist for competitors attempting to launch niacin under US 6,406,715?

The excerpted claims create a specific generic entry risk: a generic intermediate-release niacin product (once daily) that contains a swelling agent and yields urinary metabolite proportions inside the claimed ranges for the relevant dose strength could face direct infringement exposure.

Entry risk by design choice:

Higher risk
- A generic that mirrors swelling-agent controlled intermediate-release tablets with comparable pharmacokinetic-to-metabolite urine ratios.
Reduced risk levers
- Use of non-swelling excipients or a different release mechanism.
- Producing urinary metabolite distributions outside the claimed nicotinic acid and Pathway 2 metabolite percentage bands.
- Dose strategy that avoids the claimed “about” dosing groups tied to the urinary ratio gates.

Which tablet strengths are explicitly covered by dependent claims?

US 6,406,715 explicitly covers tablet-splitting configurations tied to total dose groups:

Claim set	Release type	Total dose recited	Tablet configuration	Nicotinic acid per tablet
Claims 1–4	Intermediate	~1000 mg	Two tablets	~500 mg each
Claims 5–8	Immediate	~1500 mg	Two tablets	~750 mg each
Claims 9–12	Intermediate	~2000 mg	Two tablets	~1000 mg each
Claims 13–16	Intermediate	~2500 mg	Three tablets	~1000 mg each

The independent performance requirements (urinary metabolite ratios) are coupled to these dose categories, so a design that stays within a covered split but shifts the formulation to change metabolite ratios could change infringement exposure.

How does US 6,406,715 compare with typical sustained-release niacin patent strategies?

Typical niacin product patents often center on:

release kinetics (dissolution profiles, time to release),
specific polymers/matrices,
and manufacturing parameters.

US 6,406,715 is closer to a pharmacodynamic/performance-defined formulation patent because it constrains urinary metabolite distribution percentages. In practice, this shifts freedom-for-design litigation toward:

biomarker reproducibility,
assay methodology alignment,
and demonstration that the accused product achieves (or does not achieve) the claimed urinary ratio gate.

Key Takeaways

Claim scope is gated by urinary metabolite ratios tied to dose groups (about 1000 mg, 1500 mg, 2000 mg, 2500 mg) and to the proportion of “nicotinic acid” versus “Pathway 2 metabolites” in urine.
Formulation is anchored to nicotinic acid plus a swelling agent with once-daily single-dose oral administration for hyperlipidemia.
Safety targets are embedded as discontinuation triggers: avoid hepatotoxicity and elevations in uric acid and/or glucose.
Dependent claims lock tablet splitting: 500 mg (2 tablets), 750 mg (2 tablets), 1000 mg (2 or 3 tablets) tied to the corresponding dose categories.
Enforceability hinges on (i) the definition/measurement of “Pathway 2 metabolites” and (ii) whether accused products achieve the claimed urine percentage envelopes.

FAQs

What elements must an accused product satisfy to infringe US 6,406,715?
Nicotinic acid + swelling agent in a once-daily oral regimen meeting the claimed release category, plus urine metabolite ratios (nicotinic acid and Pathway 2 metabolites) within the dose-specific ranges.
Do the claims cover both immediate-release and intermediate-release niacin?
The claim set includes intermediate-release independent claims (1, 9, 13) and an immediate-release independent claim (5), each with its own dose-linked urinary metabolite ratio ranges.
How do tablet strength limitations affect design-around options?
Dependent claims specify tablet counts and per-tablet nicotinic acid amounts for the dose categories, so deviating from those tablet-splitting formats can reduce coverage, though independent claims may still be implicated depending on overall dosing and performance.
Why is “Pathway 2 metabolites” central to validity and infringement?
It is quantified in urine as a percentage complement to urinary nicotinic acid and is likely tied to the patent’s metabolic pathway definitions and assay methods.
Can a competitor avoid infringement by changing dissolution profiles but matching plasma exposure?
The patent’s claim gate is urine metabolite distribution percentages; shifting dissolution to alter metabolite ratios can change infringement exposure even if exposure profiles overlap.

References (APA)

United States Patent No. 6,406,715. (n.d.). Intermediate release nicotinic acid formulations with urinary metabolite profile.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	289197	⤷ Start Trial
Australia	4751802	⤷ Start Trial
Australia	6348198	⤷ Start Trial
Australia	6454598	⤷ Start Trial
Australia	775967	⤷ Start Trial
Brazil	9815454	⤷ Start Trial
Brazil	9815457	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,406,715

Summary for Patent: 6,406,715